Table 2 Association of 38-gene HGF signature with breast cancer clinical and genomic subtypes and risk of recurrence (ROR) genomic score
From: Hepatocyte growth factor pathway expression in breast cancer by race and subtype
| Â | HGF negative, N (%) | HGF positive, N (%) | Multivariable RFDa (95% CI) |
|---|---|---|---|
Total (N) | 1329 (68%) | 628 (32%) | Â |
IHC-based | Â | Â | Â |
 HR−/HER2+ | 62 (57%) | 46 (43%) | 29.42% (19.91, 38.93) |
 TNBC | 86 (18%) | 391 (82%) | 69.04% (64.95, 73.14) |
 HR+/HER2− | 1053 (89%) | 125 (11%) | Referent |
 TNBC | 86 (18%) | 391 (82%) | 65.85%. (61.71, 69.98) |
 Non-TNBC | 1115 (87%) | 171 (13%) | Referent |
RNA-based-PAM50 | Â | Â | |
 Luminal B | 288 (94%) | 19 (6%) | 1.31% (− 1.51, 4.12) |
 HER2-enriched | 122 (68%) | 58 (32%) | 27.29% (20.32, 34.27) |
 Basal-like | 45 (8%) | 493 (92%) | 86.64% (83.73, 89.55) |
 Luminal A | 820 (96%) | 31 (4%) | Referent |
 Basal | 45 (8%) | 493 (92%) | 81.84% (78.84, 84.83) |
 Non-basal | 1230 (92%) | 108 (8%) | Referent |
 High ROR-PT | 145 (29%) | 352 (71%) | 48.20% (43.42, 52.99) |
 Low/medium ROR-PT | 1133 (81%) | 259 (19%) | Referent |